Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 9Burkitt Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 2Down Syndrome 2Waldenstrom Macroglobulinemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Ann Arbor Stage II Mantle Cell Lymphoma 1Anemia 1

Interventions

Rituximab 32fludarabine phosphate 28Cyclophosphamide 26Filgrastim 13Peripheral Blood Stem Cell Transplantation 12ibrutinib 11Bortezomib 11Lenalidomide 10alvocidib 9Cyclosporine 9tanespimycin 8Biopsy 8fludarabine 7Vincristine 7Radiotherapy 7Etoposide 7Specimen Handling 6romidepsin 5bryostatin 1 5apolizumab 5Vorinostat 5Methotrexate 5Ifosfamide 5Cytarabine 5CT-P10 5Busulfan 5temsirolimus 4laromustine 4aldesleukin 4Thalidomide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Lymphocytic, Chronic, B-Cell × dexamethasone 21-phosphate × Clear all
NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Completed
9 enrolled 8 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡